Tandem Diabetes Care Q2 2024 GAAP EPS $(0.47) Beats $(0.53) Estimate, Sales $221.910M Beat $204.902M Estimate
Portfolio Pulse from Benzinga Newsdesk
Tandem Diabetes Care (NASDAQ:TNDM) reported Q2 2024 GAAP EPS of $(0.47), beating the estimate of $(0.53). Sales were $221.910M, surpassing the $204.902M estimate and showing a 13.27% increase from last year.
August 01, 2024 | 8:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tandem Diabetes Care reported better-than-expected Q2 2024 results with a GAAP EPS of $(0.47) and sales of $221.910M, beating estimates and showing significant year-over-year growth.
The better-than-expected earnings and revenue figures, along with significant year-over-year growth, are likely to positively impact TNDM's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100